Endovascular brain-computer interface (BCI) technology firm Synchron has announced the acquisition of an equity stake in Acquandas—a leading technology provider specialising in state-of-the-art, high-precision components in healthcare and other industries.
As part of the transaction, Synchron chief executive officer (CEO) and founder Tom Oxley will join the Acquandas governance council, and Synchron chief technology officer Riki Banerjee will join as observer.
“As we pioneer functional endovascular neurotechnology, this investment strengthens our technology innovation and supply chain for our unique product offerings, beginning with brain-computer interfaces,” said Oxley.
“After many years of development in fabrication technology, I am thrilled to welcome Synchron on board as an investor,” added Acquandas CEO and founder Rodrigo Lima de Miranda. “This major investment will not only strengthen our existing partnership but will also play a pivotal role in expanding our facilities and capabilities. It serves as a testament to the readiness of our fabrication technology and our company for the market.”
As stated in a Synchron press release, Acquandas has established an “entirely new generation” of shape-memory, flexible metallic components suitable for use as medical devices. Acquandas’ capability to manufacture miniaturised structures, such as micro-patterned nitinol thin films, combined with high structure resolution and geometrical complexity, excellent biocompatibility, and improved mechanical properties, provides Synchron with “a unique product offering in the implantable medical device industry”, the release adds.
